2 results
Approved WMOCompleted
To validate 18F-Flutemetamol PET in the evaluation of plaque vulnerability.
Approved WMOCompleted
The main objective is to determine the efficacy of Lyumjev in the Inreda AP system. Secondary objectives are: to assess safety, differences in pharmacodynamics and differences in AP-related outcome measures.